## Active substances set

Search phrase: Acute myeloid leukemia

Below you will find a list of active substances registered by the European Medical Agency (EMA) in the last 15 years, recommended by the European Society of Clinical Oncology (ESMO) and their reimbursement status in the country.

## Acute myeloid leukemia

|  | Decitabine is indicated for the treatment of adult patients |
| :--- | :--- |
| with newly diagnosed de novo or secondary acute myeloid |  |
| Decitabine $\quad$leukaemia (AML), according to the World Health <br> Organisation (WHO) classification, who are not candidates <br> for standard induction chemotherapy. |  |

Gemtuzumab Ozogamicin is indicated for combination therapy with daunorubicin (DNR) and cytarabine (AraC) for

Gemtuzumab the treatment of patients aged 15 years and above with $\begin{aligned} \text { OZOgamicin } & \begin{array}{l}\text { previously untreated, de novo CD33-positive acute myeloid } \\ \text { leukaemia (AML), except acute promyelocytic leukaemia }\end{array}\end{aligned}$ $\begin{aligned} & \text { OZOgamicin } \text { previously untreated, de novo CD33-positive acute myeloid } \\ & \text { leukaemia (AML), except acute promyelocytic leukaemia }\end{aligned}$ (APL). (APL)


REIMBURSEMENT WITH RESTRICTIONS

Venetoclax in combination with a hypomethylating agent is indicated for the treatment of adult patients with newly diagnosed acute myeloid leukaemia (AML) who are ineligible for intensive chemotherapy.
(
REIMBURSEMENT WITH RESTRICTIONS
Venetoclax


ESMO

Midostaurin is indicated in combination with standard daunorubicin and cytarabine induction and high-dose cytarabine consolidation chemotherapy, and for patients in complete response followed by Midostaurin single agent maintenance therapy, for adult patients with newly diagnosed acute myeloid leukaemia (AML) who are FLT3 mutation-positive.

Daunorubicin / Cytarabine is indicated for the treatment of Daunorubicin / adults with newly diagnosed, therapy-related acute myeloid

FULL

Cytarabine leukaemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC).

ESMO

Gilteritinib is indicated as monotherapy for the treatment of
FULL
Gilteritinib adult patients who have relapsed or refractory acute

REIMBURSEMENT myeloid leukaemia (AML) with a FLT3 mutation.

